Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00939276 · ClinicalTrials.gov registry record · Phase 3
Macular Edema Incidence/Severity Reduction With Nevanac
A Phase 3 study, sponsored by Alcon Research.
- Terminated
- Registry status
- Phase 3
- Development phase
- 175
- Enrollment target
NCT00939276: Clinical Trial Phase 3 study, sponsored by Alcon Research.
NCT00939276 is a Phase 3 study that was terminated before completion, run by Alcon Research. The registered enrollment target is 175 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00939276, a Phase 3 study, was terminated before completion, sponsored by Alcon Research.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 175 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate NEVANAC in patients with diabetic retinopathy who developed macular edema (ME) within 90 days following cataract surgery.
Interventions
- DRUG Nepafenac ophthalmic suspension, 0.1% (NEVANAC®)
- DRUG Nepafenac ophthalmic suspension vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-08 |
| Phase | Phase 3 |
Why NCT00939276 stopped before completion
NCT00939276 is an interventional study that assigns participants to a tested intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Nepafenac ophthalmic suspension, 0.1% (NEVANAC®) is the first listed.
NCT00939276 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00939276 about?
NCT00939276 is a clinical study titled "Macular Edema Incidence/Severity Reduction With Nevanac". The purpose of this study is to evaluate NEVANAC in patients with diabetic retinopathy who developed macular edema (ME) within 90 days following cataract surgery.
What is the current status of trial NCT00939276?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 175 participants. The study started on 2009-08. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00939276?
The interventions under investigation include: Nepafenac ophthalmic suspension, 0.1% (NEVANAC®) (DRUG), Nepafenac ophthalmic suspension vehicle (DRUG).
Who is sponsoring clinical trial NCT00939276?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00939276's enrollment target sits among peer trials
175 1440th of 2000 higher than 559 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04722341 · 175 participants · NA
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- NCT05094037 · 175 participants · NA
Orthotic Treatment of Diabetic Foot Ulcers
- NCT05165745 · 175 participants · NA
Stick2PrEP Cisgender Women and Trans Individuals
- NCT05312255 · 175 participants · NA
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia